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Background: HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to
chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and
interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic
trioxide to zidovudine and IFN.
Results: Here we assessed Th1/Th2/Treg cytokine gene expression profiles in 16 ATL patients before and 30
days after treatment with arsenic/IFN/zidovudine, in comparison with HTLV-I healthy carriers and sero-negative
blood donors. ATL patients at diagnosis displayed a Treg/Th2 cytokine profile with significantly elevated
transcript levels of Foxp3, interleukin-10 (IL-10), and IL-4 and had a reduced Th1 profile evidenced by
decreased transcript levels of interferon-γ (IFN-γ) and IL-2. Most patients (15/16) responded, with CD4+CD25+
cells significantly decreasing after therapy, paralleled by decreases in Foxp3 transcript. Importantly, arsenic/IFN/
zidovudine therapy sharply diminished IL-10 transcript and serum levels concomittant with decrease in IL-4
and increases in IFN-γ and IL-2 mRNA, whether or not values were adjusted to the percentage of CD4+CD25+
cells. Finally, IL-10 transcript level negatively correlated with clinical response at Day 30.
Conclusions: The observed shift from a Treg/Th2 phenotype before treatment toward a Th1 phenotype after
treatment with arsenic/IFN/zidovudine may play an important role in restoring an immuno-competent
micro-environment, which enhances the eradication of ATL cells and the prevention of opportunistic
infections.
Keywords: Arsenic, Interferon, Zidovudine, HTLV-I, ATL, Cytokines, Immune deficiency* Correspondence: MahmoudiM@mums.ac.ir; bazarbac@aub.edu.lb
3Immunology Research Centre Bu-Ali Research Institute, Mashhad University
of Medical Sciences, Mashhad, Iran
7Department of Internal Medicine, American University of Beirut, Beirut,
Lebanon
Full list of author information is available at the end of the article
© 2013 Kchour et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kchour et al. Retrovirology 2013, 10:91 Page 2 of 12
http://www.retrovirology.com/content/10/1/91Background
Adult T-cell leukemia/lymphoma (ATL) is an aggressive
malignancy of mature activated T-cells caused by human
T cell lymphotropic virus type I (HTLV-I) [1,2]. ATL
carries a very bad prognosis because of intrinsic chemo-
resistance [3-6]. Moreover, ATL patients are functionally
severely immunocompromised and may develop a var-
iety of opportunistic infections, which further contribute
to the poor prognosis [7-9]. These include cytomegalo-
virus, Pneumocystis carinii pneumonias, malignant stron-
gyloidosis, crusted (Norwegian) scabies, disseminated
cryptococcosis, toxoplasmosis, or fungal infections, as well
as bacterial infections particulary of the respiratory tract
or of the lower urinary, and septicemias.
HTLV-1 primarily infects CD4+ T helper (Th) cells
that play a central role in adaptive immune responses.
These Th cells are the predominant viral reservoir in the
peripheral blood [10] and are normally classified into
four major lineages: Th1, Th2, Th17, and T regulatory
(Treg) cells, which produce interferon-γ (IFN-γ),
interkeukin-4 (IL-4), IL-17, and IL-10, respectively [11].
Treg are a subset of CD4
+CD25+ T cells characterized by
the expression of the transcriptional regulator Foxp3
[12] and the secretion of high levels of IL-10. In healthy
individuals, Treg cells maintain immune homeostasis and
protect against effector responses to autoantigens or
over-exuberant responses to exogenous antigens [13].
Th1 effector cells produce IFN-γ and IL-2, play a critical
role in cellular immunity against viral infections, and
determine a greater inflammatory response. Th2 cells
produce IL-4 and stimulate humoral or allergic re-
sponses. Under normal conditions, there is a Th1/Th2
cytokine balance that is disrupted when infectious agents
induce an overproduction of the Th2 cytokines, leading to
the inhibition of the adaptive immune response against
the pathogen.
The immune-suppression in ATL patients is likely me-
diated by cytokines directly produced by the ATL cells
or by ATL-triggered disruption of the normal cytokine
balance produced by normal immune cells. Furthermore,
ATL cells may directly function as Treg cells and sup-
press normal effector T cells [14-17]. Overall, this im-
munosuppressive micro-environment enables ATL cells
to evade the host immune response. Unfortunately,
chemotherapy further exacerbate this phenomenon.
After 30 years of research on HTLV-I and associated
diseases, treatment of ATL patients remains a challenge
[3,6,18-20]. In acute ATL, Japanese trials demonstrated
that although chemotherapy combinations improve re-
sponse rate, they fail to achieve a significant impact on
survival [21,22]. Patients with chronic and smoldering
ATL have a better prognosis but long-term survival is
poor when these patients are managed with a watchful-
waiting policy or with chemotherapy [23]. Recently, aworldwide meta-analysis revealed that the combination
of zidovudine and interferon-alpha (IFN) is highly effect-
ive in the leukemic subtypes of ATL and should be con-
sidered as standard first line therapy in that setting [24].
This combination has changed the natural history of the
disease through achievement of significantly improved
long-term survival in patients with smoldering and
chronic ATL as well as a subset of patients with acute
ATL [24]. ATL lymphoma patients still benefit from
chemotherapy induction with concurrent or sequential
antiretroviral therapy with zidovudine and IFN. Yet, most
patients relapse and alternative therapies are mandatory.
In prior studies, using an in vitro model of ATL derived
cell lines and freshly isolated ATL leukemic cells, we
showed that arsenic trioxide synergizes with IFN to induce
G1 arrest and apoptosis in ATL [25] through shut-off of
the NF-кB pathway and Tax degradation by the prote-
asome [26,27]. This combination yielded promising clin-
ical results in relapsed/refractory ATL patients [28]. We
recently showed that arsenic/IFN combination cures ATL
mice through selective targeting of leukemia initiating cell
(LIC) activity [29]. Finally, we reported an unprecedented
100% response rate including 70% complete remission rate
in newly diagnosed chronic ATL patients treated with
the combination of arsenic, interferon and zidovudine
(arsenic/IFN/zidovudine) [30].
In the current study, we investigated the effect of the
triple combination of arsenic/IFN/zidovudine on the im-
mune micro-environment in ATL patients. We show that
ATL patients at diagnosis displayed a Treg/Th2 cytokine
production profile. Strikingly, after therapy, the cytokine
production balance shifted from this initial “immunosup-
pressive-like” state towards an “immunocompetent-like”
state (Th1 profile). This study provides insights on the
mechanism of action of this potentially curative combin-
ation on the immune micro-environment in ATL patients.
This immunological switch may participate in the defense
against opportunistic infections as well as in the anti-
tumor immunity.
Results
Arsenic/IFN/zidovudine treatment induced a high
response rate in ATL patients
Sixteen previously untreated ATL patients (2 acute ATL, 2
ATL lymphoma, and 12 chronic ATL) received arsenic/
IFN/zidovudine treatment. The patients’ characteristics
are listed in Table 1. Clinical data, response to therapy and
follow up data were previously reported for 10 of these
patients [30]. Briefly, all patients initially presented with
symptomatic disease requiring treatment. The most fre-
quent symptoms were cutaneous manifestations with
maculopapular rash, severe itching, and skin ulcerations.
At day 30 and as previously reported [30], treatment with
arsenic, IFN, and AZT resulted in a good albeit partial
Table 1 Patients characteristics
Patient age Gender ATL subtype Response at day 30 Best response Initial viral load (copy/μl) Viral load at day 30 (copy/μl)
58 F Acute PR PR 105483 219
56 M Acute PR PR NA NA
60 M Chronic PR CR NA NA
47 F Chronic VGPR CR 1990 336
53 M Chronic PR CR 84 33
72 M Chronic VGPR CR 548 0
36 M Chronic VGPR VGPR 999 838
46 F Chronic VGPR CR NA NA
63 F Chronic PR CR 1081 63
51 F Chronic PR CR 196 64
68 F Chronic VGPR VGPR 1805 65
60 M Chronic PR CR 47 7
53 M Chronic PR PR 49724 18898
77 M Chronic VGPR CR 3747 182
54 M Lymphoma NR NR NA NA
48 M Lymphoma PR CR NA NA
CR= complete remission; PR= partial response; VGPR= very good partial response; NR= No response; NA= not available.
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tients achieved partial response (PR) and 6 patients
achieved very good partial response (VGPR), as described
in Patients and Methods. One ATL lymphoma died from
disease progression (Table 1). Interestingly, as previously
reported in seven patients [30], in the eleven patients for
whom initial and Day 30 DNA was available, HTLV-I pro-
viral load significantly decreased from an average of 1415
copy/μl of blood to 226 copy/μl (p<0.05). Most patients
continued to improve their response and the best response
was achieved within 2 to 4 months. Indeed, out of the 15
responding patients, 10 patients achieved CR, 2 patients
achieved VGPR (solely because of the presence of 6% and
8% of atypical lymphocytes on peripheral blood smear,
respectively), and three patients achieved PR (Table 1).
We examined the effect of treatment on the relative dis-
tribution of the T cell subpopulations at day 30 (Table 2).
Treatment with arsenic, AZT, and IFN decreased the aver-
age percentage of CD4+ cells (from 87 ± 14% to 77 ± 21%;
p<0.01) and increased the average percentages of CD8+
cells (from 12 ± 12% to 16 ± 12%; p<0.01). In accordance
with the observed response to therapy, a decrease in the
average percentage of CD4+CD25+ cells was noted in all
patients after treatment (from 47 ± 15% to 25 ± 14%;
p<0.001), suggesting that this combination is mainly acting
on the circulating malignant cells and HTLV-I infected
cells (Table 2).
Arsenic/IFN/zidovudine treatment decreased transcript
levels of Treg and Th2 markers
We investigated the early effect of the triple combination
(arsenic/IFN/zidovudine) on the Treg subpopulation byevaluating the transcript levels of Foxp3 and IL-10 in 10
healthy sero-negative blood donors, 10 asymptomatic
HTLV-I healthy carriers, as well as in 16 ATL patients
before and 30 days after treatment, before achievement
of maximal response.
Untreated ATL patients displayed significantly higher
transcript levels of Foxp3 (Figure 1A) and IL-10
(Figure 2A), relative to seronegative or healthy carrier
individuals (p < 0.05). Notably, Foxp3 and IL-10 mRNA
levels in untreated ATL patients were, respectively, at least
12 and 53 folds higher than seronegative and healthy car-
rier individuals (p < 0.05). High interindividual variation
was observed among ATL patients for both Foxp3 and
IL-10 transcript levels (Figures 1A and 2A, Table 3).
Interestingly, treatment with arsenic/IFN/zidovudine
significantly decreased transcript levels of both Foxp3
(Figure 1B) and IL-10 (Figure 2B). Because ATL cells
express a Treg phenotype, we normalized the expres-
sion levels of Foxp3 and IL-10 relative to the percent-
age of CD4+ CD25+ cells. ATL patients still showed
significantly higher normalized transcript levels of
Foxp3 and IL-10 relative to seronegative individuals
(Figures 1C and 2C; p < 0.05). Normalized mRNA
values of IL-10 (Figure 2D), but not Foxp3 (Figure 1D),
significantly decreased in ATL patients after treatment
(p < 0.05). Interestingly, standardized IL-10 transcript
level negatively correlates with clinical response at
Day 30 (r = −0.452, p < 0.05, spearman). This correl-
ation remained valid even when adjusted for the con-
founder effects of gender and/or age. This suggests
that the lower the IL-10 levels before therapy, the
better the response after 30 days of therapy.
Table 2 Flow cytometry analysis of T cell surface markers at initiation (Before) and 30 days after (After) treatment with
arsenic/IFN/zidovudine, SD, standard deviation
Patient
age
CD4+ cell/μl % CD4+ cells CD8+ cell/μl % CD8+ cells %CD4+/ CD25+ cells
Before After Before After Before After Before After Before After
58 185710 90528 100 96 1857 1886 1 2 52 32
56 77040 2592 100 89 770 262 1 9 65 41
60 7020 3240 82 82 1320 1120 14 18 53 35
47 250 194 90 98 6318 3175 8 12 55 33
53 779 594 59 53 488 459 37 41 50 14
72 31142 4317 91 86 3080 703 9 14 44 25
36 5100 1584 93 90 5050 1095 7 10 48 42
46 4989 2072 85 67 3934 2360 15 33 58 22
63 4335 1061 80 42 765 523 20 28 41 7
51 1010 307 98 94 4269 1650 2 6 18 10
68 4989 1989 100 96 50 21 1 1 50 15
60 48370 15657 82 82 7980 2730 14 18 25 18
53 274 84 93 89 44984 13935 7 11 70 54
77 4469 1119 56 41 2873 764 36 28 52 25
54 1333 304 80 49 300 112 18 18 16 7
48 2160 2226 100 96 1 1 1 1 55 26
Mean 87 77 12 16 47 25
SD 14 22 12 12 15 14
P value <0.01 <0.01 <0.001
P values indicate the significance level for the pairwise comparisons between “Before” and “after”.
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patients, we assessed the secretion of this cytokine in the
serum of patients by ELISA before and 30 days after
treatment. Seven patients had significantly higher IL-10
serum levels relative to seronegative and healthy carrier
individuals (Figure 2E; p < 0.001) and all displayed de-
creases in IL-10 serum levels after treatment (Figure 2F;
p < 0.01). Interestingly, these seven patients are those
who displayed the highest IL-10 mRNA expression be-
fore treatment (Figure 2A). IL-10 serum levels were low
before and after treatment in the remaining patients
(data not shown). These results suggest that treatment
with arsenic/IFN/zidovudine decreases the proportion of
ATL cells with Treg phenotype as well as their IL-10
production.
We then assessed the effect of treatment on the Th2
subpopulation by evaluating the transcript levels of
IL-4. ATL patients had significantly higher levels of
IL-4 mRNA (Figure 3A; p < 0.05), but not of normal-
ized IL-4 transcripts (Figure 3C), compared to healthy
carriers and seronegative blood donors. Treatment
with arsenic/IFN/zidovudine significantly decreased
IL-4 and normalized IL-4 expression (Table 3 and
Figure 3B and 3D; p < 0.05). Interestingly, the de-
crease in IL-4 expression was more pronounced in
the patients who had the highest pretreatment tran-
script levels (Table 3 and Figure 3B and D).Treatment with arsenic/IFN/zidovudine increased
transcript levels of Th1 markers
We finally investigated the effect of arsenic/IFN/zidovudine
treatment on the Th1 subpopulation by evaluating the
transcript levels of IFN-γ and IL-2. ATL patients
exhibited significantly lower mRNA levels of IFN-γ
(Figure 4A) and normalized IFN-γ (Figure 4C), rela-
tive to seronegative or healthy carrier individuals (p <
0.05). Similarly, IL-2 (Figure 5A) and normalized IL-2
(Figure 5C) mRNA levels were lower in ATL patients,
compared to seronegative individuals, with only nor-
malized values being statistically significant (p < 0.001).
Interestingly, treatment with arsenic/IFN/zidovudine sig-
nificantly increased the expression and normalized tran-
script levels of IFN-γ (Table 3 and Figure 4B and D; p <
0.001) and IL-2 (Table 3 and Figure 5B and D; p < 0.01).
Discussion
In this study, we report an early shift of the cytokine
gene expression profile from a Treg and Th2 phenotypes
towards a Th1 phenotype in ATL patients after treat-
ment with the combination of arsenic/IFN/zidovudine.
We first confirmed the previously reported high tran-
script levels of Foxp3, IL-10 [12,31,32], and, to lesser
extent, IL-4, and low transcript levels of IFN-γ and IL-2,
in untreated ATL patients as compared to HTLV-I
healthy carriers and HTLV-I negative blood donors.
Figure 1 Treatment with arsenic/IFN/zidovudine decreased Foxp3 expression. A. Foxp3 transcript levels in normal blood donors (n=10),
healthy carriers of HTLV-I (n=10) and ATL patients (n=16) at initiation and 30 days after treatment with arsenic/IFN/zidovudine. Rectangles
represent mean values. B. Mean and median Foxp3 transcript levels of individual ATL patients at initiation and 30 days after treatment with
arsenic/IFN/zidovudine. C, D. Relative expression of Foxp3 transcripts after normalization to the number of CD4+CD25+ ATL cells. All values are
expressed as percentage of human beta2-microglobulin used as internal control. *, **, *** indicate p values less than 0.05, 0.01 and
0.001 respectively.
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compromised micro-environment characterized by a dis-
ruption of the normal cytokine balance, which is skewed
toward Treg and Th2 responses. This micro-environment
helps ATL cells to evade the immune surveillance and
likely explains the frequent opportunistic infections en-
countered in ATL patients.
The mechanisms of this disruption of the immune sys-
tem in ATL patients have been extensively investigated.
Previous reports indicated that ATL cells functionally
and phenotypically resemble Treg cells [13-17]. Indeed,
two thirds of ATL cases harbor leukemic cells expressing
Foxp3 [33-35]. Furthermore, most ATL cells express Treg
markers (CD4, CD25, and Foxp3) suggesting that ATL
originates in natural Treg cells infected with HTLV-1
[15,31]. These Treg-like ATL cells do not produce IFN-γ
[31,36] contrary to the HTLV-I infected CD4+CD25+
cells in the neuro-inflammatory HTLV-I Associated
Myelopathy/Tropical Spastic Paraparesis (HAM/TSP),
which display a non-Treg phenotype with decreased ex-
pression of Foxp3 and increased levels of IFN- γ [37-41].
Moreover, ATL patients display elevated IL-10 transcript
levels contrary to normal T cells [42] and high IL-10
serum level is an unfavorable prognostic factor amongATL patients [31] as well as in HTLV-I negative Hodgkin
and non-Hodgkin lymphomas and chronic lymphocytic
leukemia [43]. Interestingly, in our study IL-10 tran-
script level negatively correlates with response at Day
30 (r = −0.452, P < 0.05, spearman), whereas no sig-
nificant correlations were observed between the stan-
dardized expression levels of the other cytokines and
response at Day 30 (P > 0.05, spearman). Hence, IL-
10 transcript level can be used as biomarker to pre-
dict response to arsenic/IFN/zidovudine. Finally, in ATL,
IL-10 has strong immunosuppressive effects since it in-
hibits the proliferation of normal T cells and the expres-
sion of Th1 associated cytokines IFN-γ and IL-2 [44,45].
Thus, excessive production of IL-10 by ATL cells may im-
pair the host’s immune system resulting in an immuno-
suppressive state.
Several studies have demonstrated the role of Th1
cytokines in the control of tumor growth and HTLV-I
expression. IL-2 withdrawal was found to induce HTLV-I
expression in ATL cell lines [46]. Also, deficiency in IFN-γ
resulted in an enhanced tumorigenesis in HTLV-I tax
transgenic mice [47]. On the other hand, adenovirus-
mediated IFN-γ transfer inhibited the growth of
transplanted HTLV-I Tax tumors in mice [48]. IFN-γ is
Figure 2 Treatment with arsenic/IFN/zidovudine decreased IL-10 expression and serum levels. A. IL-10 transcript levels in normal blood
donors (n=10), healthy carriers of HTLV-I (n=10) and ATL patients (n=16) at initiation and 30 days after treatment with arsenic/IFN/zidovudine.
Rectangles represent mean values. B. Mean and median IL-10 transcript levels of individual ATL patients at initiation and 30 days after treatment
with arsenic/IFN/zidovudine. C, D. Relative expression of IL-10 transcripts after normalization to the number of CD4+CD25+ ATL cells. All values are
expressed as percentage of human beta2-microglobulin used as internal control. E, F. Levels of secreted IL-10 in the serum of the seven ATL
patients who displayed elevated pretreatment IL-10 serum level, measured by ELISA before and after treatment. *, **, *** indicate p values less
than 0.05, 0.01 and 0.001 respectively.
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immune response to HTLV-I infection [11]. ATL cells are
unresponsive in vitro to TCR stimulation and suppress
the proliferation of stimulated T cells [15]. Yano et al.
showed that leukemia cells from some ATL patients sup-
press the proliferation of autologous CD4+ non ATL cells,
secrete small amounts of IFN-γ, and suppress IFN-γ pro-
duction by autologous CD4+ non-ATL cells [49].
Importantly, as early as one month after treatment
with arsenic/IFN/zidovudine, and before achievement
of maximal clinical response, we observed significantdecreases in Foxp3, IL-10, and IL-4 transcripts and sig-
nificant increases in IL-2 and IFN-γ expression. The de-
crease of Foxp3 mRNA correlated with the decreased
percentage of CD4+CD25+ ATL cells. However, signifi-
cant decreases in IL-10, and, to a lesser extent, IL-4
transcript levels were observed even after adjustment to
the number of CD4+CD25+ leukemic cells. Previous re-
ports have shown that IL-10 and IL-4 are directly pro-
duced by ATL cells under the control of Tax-induced
NF-кB and Tax activation [50,51]. Hence, decreased IL-
10 and IL-4 transcripts in treated ATL patients is likely
Figure 3 Treatment with arsenic/IFN/zidovudine decreased IL-4 expression. A. IL-4 transcript levels in normal blood donors (n=10), healthy
carriers of HTLV-I (n=10) and ATL patients (n=16) at initiation and 30 days after treatment with arsenic/IFN/zidovudine. Rectangles represent mean
values. B. Mean and median IL-4 transcript levels of individual ATL patients at initiation and 30 days after treatment with arsenic/IFN/zidovudine.
C, D. Relative expression of IL-4 transcripts after normalization to the number of CD4+CD25+ ATL cells. All values are expressed as percentage of
human beta2-microglobulin used as internal control. *, **, *** indicate p values less than 0.05, 0.01 and 0.001 respectively.
Table 3 Foxp3 and cytokine transcript levels at initiation (Before) and 30 days after (After) treatment with arsenic/IFN/
zidovudine
Patient age Foxp3 before Foxp3 after IL-10 before IL-10 after IL-4 before IL-4 after INF-γ before INF-γ after IL-2 before IL-2 after
58 0 0 0 0 0 0 13 80 7 34
56 16 34 1372 66 2 0 4 28 9 22
60 163 15 70 6 0 0 4 16 1 6
47 4 11 69 4 3 4 5.9 18 17 64
53 43 138 34 4 12 10 11.8 124 8 67
72 12 8 0 0 2 0 0.3 16 0 0
36 197 62 2 0 7 1 4.3 17 3 32
46 6 13 2 3 0 0 0.8 8 3 43
63 12 50 14 11 3 3 7 57 1 12
51 53 28 927 112 19 3 5 22 1 3
68 12 6 23 6 1 1 6 62 1 4
60 20 11 2684 60 8 4 3 155 1 4
53 48 47 0 0 0 0 2 7 0 0
77 2 2 52 6 3 3 13 45 1 4
54 20 30 6584 4602 5 1 5 114 0 2
48 72 107 1011 286 3 2 6 25 10 45
All values are expressed as percentage of human beta2-microglobulin used as internal control.
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Figure 4 Treatment with arsenic/IFN/zidovudine increased IFN-γ expression. A. IFN-γ transcript levels in normal blood donors (n=10),
healthy carriers of HTLV-I (n=10) and ATL patients (n=16) at initiation and 30 days after treatment with arsenic/IFN/zidovudine. Rectangles
represent mean values. B. Mean and median IFN-γ transcript levels of individual ATL patients at initiation and 30 days after treatment with
arsenic/IFN/zidovudine. C, D. Relative expression of IFN-γ transcripts after normalization to the number of CD4+CD25+ ATL cells. All values are
expressed as percentage of human beta2-microglobulin used as internal control. *, **, *** indicate p values less than 0.05, 0.01 and
0.001 respectively.
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reversal of NF-кB activation [26,27,29]. Decreased IL-10
expression may alleviate the pre-existing inhibitory effect
on Th1 associated cytokines, IFN-γ and IL-2 [44,45],
likely explaining the observed increase in their transcript
levels after treatment.
This report has several limitations. First, we have only
studied the effect of the triple combination of arsenic,
IFN and zidovudine, and therefore the individual contri-
bution of each drug alone cannot be assessed. Second, in
the absence of functional immune studies, we have only
assessed cytokine expression profile which represents an
indirect demonstration of the treatment effect on the
immune micro-environment. Finally, there is no direct
evidence of the mechanism of action and whether the
shift of the cytokine expression profile is secondary to
the downregulation of HTLV-I proteins (Tax and/or
HBZ), inhibition of de-novo infection of T cells by
HTLV-I, or an HTLV-I independent mechanism. Indeed,
while these therapies are clinically quite effective, their
mechanism of action remains controversial. Several re-
ports suggested an antiviral effect of zidovudine and inter-
feron without demonstrating it [52]. Preclinical modelsdemonstrated that the combination of arsenic trioxide
and interferon eradicate human ATL cells and cures mur-
ine ATL derived from Tax transgenics through Tax deg-
radation by the proteasome [29]. However, this has not
been demonstrated in ATL patients. Finally, preliminary
reports suggested an HTLV-I independent mechanism
involving p53 and inhibition of telomerase activity [53].
Conclusions
In conclusion the shift of the cytokine expression profile
from a Treg and Th2 phenotype before treatment toward
a Th1 phenotype one month after treatment with ar-
senic/IFN/zidovudine, and before maximal clinical re-
sponse and ATL cell loss, may play an important role in
restoring an immune response that can participate in
the eradication of ATL cells and the prevention or con-
trol of opportunistic infections. Therefore, this poten-
tially curative combination can target ATL cells through
1) Tax degradation and eradication of LIC activity (ar-
senic and IFN), 2) inhibition de-novo infection of T cells
by HTLV-I (zidovudine and interferon), and 3) switch of
the immune system towards an immuno-competent
state (triple combination).
Figure 5 Treatment with arsenic/IFN/zidovudine increased IL-2 expression. A. IL-2 transcript levels in normal blood donors (n=10), healthy
carriers of HTLV-I (n=10) and ATL patients (n=16) at initiation and 30 days after treatment with arsenic/IFN/zidovudine. Rectangles represent mean
values. B. Mean and median IL-2 transcript levels of individual ATL patients at initiation and 30 days after treatment with arsenic/IFN/zidovudine.
C, D. Relative expression of IL-2 transcripts after normalization to the number of CD4+CD25+ ATL cells. All values are expressed as percentage of
human beta2-microglobulin used as internal control. *, **, *** indicate p values less than 0.05, 0.01 and 0.001 respectively.
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Patients’ description, study design and treatment
schedule
This study included 16 ATL patients. They were referred
between 2006 and 2009 to the Hematology-Oncology
Department of Ghaem and Imam Reza hospitals, Mash-
had University of Medical Sciences, Iran. All ATL pa-
tients had serologic evidence of HTLV-I infection by
Enzyme-Linked Immunosorbent Assay (ELISA). Confirm-
ation of HTLV-I positivity was done by standard Polymer-
ase Chain Reaction (PCR) (Data not shown). According to
the Shimoyama classification criteria for ATL [18], 12
patients had chronic ATL, 2 patients had acute ATL, while
the 2 remaining patients had ATL lymphoma. The
patient's characteristics are shown in Table 1. In addition
to ATL patients, this study included 10 HTLV-I healthy
carriers and 10 HTLV-I seronegative healthy volunteers
prospectively selected from the Mashhad Blood Bank
Center.
Treatment consisted of intravenous arsenic (10 mg/
day, 5 days/week), subcutaneous IFN (Pooyesh Darou
Pharmaceutical Co) (5 million units/day), and oral zi-
dovudine (900 mg/day in 3 divided doses) and was ad-
ministered to the patients for 30 days. Later on, patientsreceived maintenance therapy with zidovudine and IFN.
In case of toxicity, zidovudine and IFN were either transi-
ently interrupted or their dose was reduced to 600 mg/day
and 3 million units per day, respectively. Arsenic dose was
not reduced in case of toxicity, but arsenic treatment was
transiently interrupted.
This study was approved by the ethical committee of
Mashhad University of Medical Sciences. Blood collec-
tion was performed on all patients and control subjects
after signing informed consent forms in accordance with
the Declaration of Helsinki. Peripheral blood mono-
nuclear cells (PBMCs) and serum were obtained from all
the patients before and after 30 days of treatment.
Response criteria
Complete remission (CR) was defined as a normalization
of the CBC associated with a disappearance of all meas-
urable tumors lasting at least one month. Patients with
persistence of less than 5% atypical lymphocytes were
also considered in CR as this situation may be seen in
healthy carriers of HTLV-I. Very good partial response
(VGPR) was defined as a normalization of the CBC asso-
ciated with a disappearance of all measurable tumors
lasting at least one month, but with persistence of more
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Partial response (PR) was defined as a decrease of more
than 50% in the number of leukemia cells and in the size
of all measurable tumors. No response (NR) was defined
as less than 50% decrease in the number of leukemia
cells or in the size of any measurable tumor, or as dis-
ease progression.
Flow cytometry analysis
Red blood cells were removed using a lysis solution
(Becton Dickinson, San Diego). After fixation of white
blood cells for 20 minutes in 0.5% paraformaldehyde
solution, the cells were washed twice with PBS then im-
munostained with specific monoclonal antibodies and
incubated in dark for 20 minutes. Monoclonal antibodies
used for this study were: anti-CD4- peridinin chlorphyl
protein (PerCP) , anti-CD3- phycoerythrin (R-PE), anti-
CD25-fluorescein isothiocyanate (FITC) and anti-CD8-
PE. All monoclonal antibodies (mAbs) were purchased
from (IQ-product/Netherlands) and used at 1 in 10 dilu-
tion (10 μl of antibody in 100 μl of blood). Flow cytome-
try data was analysed using the CellQuest software
(Becton Dickinson, San Diego). Results are presented as
the relative fluorescence intensity and percentage of
gated cell populations.Quantification of Foxp3 and cytokine expression by real
time RT-PCR
Total RNA was isolated from PBMCs using a TriPure
Isolation Reagent (Roche Applied Science, Germany).
cDNA was synthesized using a RevertAidTM H minus
First Strand cDNA Synthesis Kit (Fermentas, Germany)
and stored at −20°C until use. Primers were designed at
exon-exon junctions (Beacon Designer http://WWW.
premierbiosoft.com). All of the selected primers sequences
were further analyzed with the Oligo software (http://
WWW.cambio.co.uk/index.php). Beta 2 microglobulin
(β2m) was used as internal housekeeping control gene
to normalize the mRNA expression levels.
Quantification of Foxp3 and cytokine transcript ex-
pression was performed using real-time reverse transcript-
ase (RT) PCR in a rotor gene 6000, Corbett. Taqman
method amplification was carried out for Foxp3 using the
following primers and probes: Foxp3 sense: 5′ACTAC
TTCAAgTTCCACAACATgC-3′; Foxp3 anti sense: 5′g
AgTgTCCgCTgCTTCTCTg-3′; Foxp3 probe: 5′TCAC
CTACgCCACgTTCATCCgCT3′; β2m sense: 5′CTTgT
CTTTCAgCAAggACTgg-3′; β2m antisense: 5′CCACT
TAACTATCTTgggCTgTg-3′; β2m probe: 5′TCACATgg
TTCACACggCAggCAT-3′. Thermal cycling conditions
consisted of an initial step of 10 min at 95°C, followed
by 40 cycles at 95°C for 15 s and 60°C for 1 min.
Sybergreen amplification was carried out for interleukin-2 (IL-2), IL-4, IL-10, and IFN-γ using the following
primers: IL-2 sense CTCACCAggATgCTCACATTTAAg;
IL-2 antisense CTCCAgAggTTTgAgTTCTTCTTC; IL-
4 sense: CACCgAgTTgACCgTAACAgAC; IL-4 antisense:
CCCAggCAgCgAgTgTCC; IL-10 sense: TTgCTggAgg
ACTTTAAgggTTAC; IL-10 antisense: CTTgATgTCTggg
TCTTggTTCTC; IFN-γ sense: TgggTTCTCTTgg CTg
TTACTg; IFN-γ antisense: gAgTTCCATTATCCgCTA
CATCTg; β2m sense: CTTgTCTTTCAgCAAggAC
Tgg; β2m antisense: CCACTTAACTATCTTgggCTg
Tg. Sybergreen reactions were carried out in a final
reaction volume of 20 μL using SYBR Premix EX
Taq (RR041Q, TaKaRa). Thermal cycling conditions
consisted of an initial step of 10 min at 95°C,
followed by 40 cycles at 95°C for 10s, 60°C for 30s.
For each run, a standard curve was generated using
using a five-fold dilution series of a pooled cDNA for
Foxp3, IFN-γ, IL-10, IL-2, IL-4 and β2m. The relative
standard curves for both reference and target genes
were generated by plotting the threshold cycle value
versus the log of the dilution of the cDNA. PCR effi-
ciencies (10-1/slope-1) was automatically calculated by
the Rotor Gene Q system Software.Proviral load
The HTLV-I viral copy number per μl of blood was cal-
culated from the cell count and the average viral copy
number per cell as assessed by quantitative PCR. Real-
time quantitative PCR was performed on DNA extracted
from peripheral blood mononuclear cells as previously
described, using primers and Taqman probe positioned
on tax gene and albumin gene for normalization [30].
TaqMan amplification was carried out in reaction vol-
umes of 25 μL, with the use of the qPCR MasterMix
(Eurogentec, Leuven, Belgium). Each sample was ana-
lyzed in triplicate with the use of 250 ng of DNA in each
reaction. Thermal cycling was initiated with a 2-minutes
incubation at 50°C, followed by a first denaturation step
of 10 minutes at 95°C and then by 45 cycles at 95°C for
15 seconds and 58°C for 1 minute for tax (or 60°C for 1
minute for albumin).Quantification of IL-10 serum levels
Peripheral blood samples were transferred to serum-
separating tubes and centrifuged at 1000g for 20 min
after clot formation. The supernatants were carefully
harvested, and immediately stored at −80°C until ana-
lysis. The serum IL-10 concentration was measured in
duplicate by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(R&D Systems, MN, USA). Absorbance of each well
was measured spectrophotometrically at 450 nm. The
amount of IL-10 protein in the samples was calculated
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Statistical analysis
SPSS Version 16.0 and Microsoft Office Excel 2010 were
used for statistical analyses. In scatter plots, means were
compared using ANOVA with associated post-hoc tests:
Dunnett t, Tukey, Student-Newman-Keuls (SNK), and
Bonferroni tests. All analyzed samples fit normal distri-
butions, except IFN-γ and IL-10 values in ATL patients.
Therefore, both mean and median were plotted for ATL
patient data, as shown in line diagrams, and were ana-
lyzed using parametric and nonparametric (Wilcoxon)
paired sample t-tests, respectively, to compare values be-
fore and after treatment. In all cases, mean and median
either both showed statistical significance or both not.
For normally distributed data, pearson correlation was
performed. Otherwise, spearman correlation was used and
compared to pearson’s rho tested on log-transformed data,
with similar results. Spearman rho was employed for cor-
relations involving ordinal scale data. Statistical signifi-
cance was reported when the P-value was ≤ 0.05, except
in scatter plots comparing ATL patients before and after
treatment, for which P-values were stated separately in
line diagrams. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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